Salus Ljubljana dd

Salus Ljubljana dd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.33, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow of EUR 9.59 million supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics show a return on equity of 18.39% and a return on assets of 6.58%, both of which are strong relative to the industry median. The company's operating margin of 2.83% (calculated from operating income of EUR 19.67 million on revenue of EUR 696.19 million) is in line with industry norms, but its gross margin of 8.97% (calculated from gross profit of EUR 62.47 million) is below the median for pharmaceutical firms, suggesting potential inefficiencies in production or pricing.

The company's revenue is concentrated in a single geographic region, primarily Slovenia and neighboring European countries, with no disclosed international diversification. This concentration increases exposure to local economic and regulatory shifts. No segment-specific revenue breakdown is available, but the company operates as a single business unit focused on pharmaceuticals.

Growth trajectory is modest, with no disclosed revenue growth over the past year. The company's capital expenditure of EUR -6.83 million indicates a reduction in investment, which may signal a focus on cost control or asset optimization. Looking ahead, the company is expected to maintain a stable revenue profile, with no significant growth or contraction anticipated in the next fiscal year.

Risk factors include medium liquidity risk due to the current ratio and negative net cash position. The company has a low dilution risk, with no difference between basic and diluted shares outstanding. No recent equity issuance or ATM/shelf registration is disclosed, and no dilution-related risk factors are identified in the 10-K or other filings.

Recent events include the publication of the latest financial report, which highlights stable operating performance and a focus on maintaining profitability amid cost pressures. No material regulatory or litigation events were disclosed in the most recent filings, and the company has not issued any significant earnings guidance or strategic announcements in the past quarter.